grant
Evaluating the impact of TP53 mutation on the epigenetic therapy viral mimicry response in the non- small cell lung cancer tumor
Organization WEST VIRGINIA UNIVERSITYLocation MORGANTOWN, UNITED STATESPosted 1 Jul 2025Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY2025Active OxygenAddressAffectAlteration in RespirationAlternative TherapiesAlternative interventionAnimal ModelAnimal Models and Related StudiesAnti-OncogenesAnti-viral ResponseAntioncogene Protein p53AntioncogenesB7-H1BindingBinding SitesCD274Cancer CauseCancer EtiologyCancer Suppressor GenesCancer TreatmentCancersCategoriesCell Communication and SignalingCell LineCell SignalingCell-Mediated Lympholytic CellsCellLineCellular Tumor Antigen P53Cessation of lifeCharacteristicsCheckpoint inhibitorChromatinChronicClinicalClinical EvaluationClinical TestingCo-cultureCocultivationCocultureCoculture TechniquesCodonCodon NucleotidesCombining SiteComplementComplement ProteinsConsensusCytolytic T-CellCytosolCytotoxic T CellCytotoxic T-LymphocytesDNADNA Binding DomainDNA DamageDNA InjuryDNA Methyltransferase InhibitorDNA mutationDNA-Binding Protein MotifsDataDeathDeoxyribonucleic AcidDevelopmentDoseDouble-Stranded RNAERVsEmerogenesEndogenous RetrovirusesEnvironmentExpression SignatureFibroblastsGene ActivationGene ExpressionGene Expression ProfileGene TranscriptionGenesGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGoalsHERVsHuman Endogenous RetrovirusesHypermethylationIFNImmuneImmune EvasionImmune checkpoint inhibitorImmune mediated therapyImmune responseImmune signalingImmunesImmunologic SubtypingImmunologically Directed TherapyImmunomodulationImmunophenotypingImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyIn VitroInterferonsIntracellular Communication and SignalingKinasesLinkMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungManuscriptsMediatingMissense MutationMitochondriaMitochondrial DNAModalityModelingMolecularMolecular InteractionMutateMutationNGS MethodNGS systemNSCLCNSCLC - Non-Small Cell Lung CancerNational Institutes of HealthNon-MalignantNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaOnco-Suppressor GenesOncogenes-Tumor SuppressorsOncoprotein p53OntologyOrganoidsOutcomeOutputOxidative PhosphorylationOxidative Phosphorylation PathwayOxygen RadicalsP53PD-1/PD-L1PD-1/PDL1PD-L1PD1-PD-L1PD1/PD-L1PD1/PDL1PDL-1Pathway interactionsPatientsPhenotypePhosphoprotein P53Phosphoprotein pp53Phosphotransferase GenePhosphotransferasesPlayPreclinical dataPro-OxidantsProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1Protein TP53ProtocolProtocols documentationPublishingPulmonary CancerPulmonary malignant NeoplasmRNA ExpressionReactive Oxygen SpeciesReactive SiteRecessive OncogenesReportingReproducibilityResearchRespirationRoleShapesSignal TransductionSignal Transduction SystemsSignalingStimulator of Interferon GenesStrains Cell LinesTP53TP53 geneTRP53TechnologyTestingTherapeuticTransactivationTranscriptionTranscription AlterationTranslationsTransphosphorylasesTreatment EfficacyTreatment outcomeTumor CellTumor Protein p53Tumor Protein p53 GeneTumor Suppressing GenesTumor Suppressor GenesTumor Suppressor ProteinsUnited StatesUnited States National Institutes of HealthUpregulationViralVirus Inhibitorsaberrant protein foldingabnormal protein foldingadvanced diseaseadvanced illnessanti-cancer therapyanti-tumor immune responsebiological signal transductioncGAMP STINGcGAMP-STINGcGAMP/STINGcGAS/STINGcancer microenvironmentcancer therapycancer-directed therapyclinical relevanceclinical testclinical translationclinically relevantclinically translatablecombinatorialcomplementationcultured cell linecyclic GMP-AMP synthase/STINGdemethylationderepressiondesigndesigningdevelopmentaldsRNAepigenetic drugepigenetic modifying drugsepigenetic therapygene expression patterngene expression signaturegenome mutationgenome scalegenome-widegenomewidehost responseimmune check point inhibitorimmune evasiveimmune microenvironmentimmune modulationimmune regulationimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentimprovedindividualized therapeuticinhibitorinsightintervention efficacykiller T cellknowledge baselung cancermalignancymimicryminimize animal testingminimize animal usemissense single nucleotide polymorphismmissense single nucleotide variantmissense variantmitochondrialmitochondrial dysfunctionmodel of animalmtDNAmutantneoplasm/cancerneoplastic cellnext gen sequencingnext generation sequencingnextgen sequencingnonmalignantnoveloncosuppressor genep53 Antigenp53 Genesp53 Tumor Suppressorpathologic protein foldingpathwaypersonalization of treatmentpersonalized medicinepersonalized therapeuticpersonalized therapypersonalized treatmentpre-clinicalpreclinicalpreclinical findingspreclinical informationprogrammed cell death ligand 1programmed cell death protein ligand 1programsprotein death-ligand 1protein foldingprotein misfoldingprotein p53recruitreduce animal experimentationreduce animal model usereduce animal testingreduce animal usereduce dependence on animalsreduce reliance on animalsreducing animal numbersreducing animal studiesresearch clinical testingrespiratory mechanismresponsescRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsocial rolesurvival outcometherapeutic efficacytherapeutic outcometherapy efficacytherapy outcometooltrans-activationtranscriptional profiletranscriptional signaturetranslationtreatment strategytumortumor immune microenvironmenttumor microenvironmenttumor suppressortumor-immune system interactionsviral inhibitor
Description preview
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the United States. FDA approval
of immunotherapy represents a major therapeutic advance, but long-term survival remains limited, and combinatorial
approaches that maximize antitumor immune responses are an urgent clinical priority.
Low-dose DNA methyltransferase…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click